nVasive: An AI and Machine Learning Approach for Metastasis Prediction Using nVasive and Microgravity

Cancer is a leading cause of global morbidity and mortality, with metastasis responsible for 90% of cancer-related deaths. Predicting metastatic behavior remains a critical challenge in oncology. Encapsulate’s nVasive is an automated tumor-on-a-chip (TOC) platform that grows patient-derived microtumors ex vivo, preserving their native tumor microenvironment. By enabling high-throughput imaging and real-time monitoring, nVasive provides a unique approach to studying cancer invasion dynamics under both normal gravity and microgravity (µG) conditions. µG offers an unparalleled environment for metastasis research by minimizing external mechanical forces, allowing cancer cells to retain native phenotypic and genotypic properties. Our proprietary biochip uses degradable hydrogels to track tumor invasion as cells migrate into a secondary chamber, where their motility and behavior are analyzed. Our SpaceX CRS-30 experiments validated nVasive’s capability to distinguish metastatic from non-metastatic cells in µG, revealing measurable differences in motility and genetic responses. Following our 2020-2023 ISS National Lab project with Space Tango (ISSNL CASIS #: GA2019-7750), we secured approval for two additional NASA missions and now seek funding to expand nVasive through: 1. AI-Driven Image Processing and Clinical Integration: Develop machine learning algorithms to analyze tumor motility patterns and correlate µG-derived invasion data with patient clinical and genetic profiles for real-time metastasis risk assessment. 2. Metastasis Simulation: Build computational models to simulate metastasis in µG, offering predictive insights for oncology research and experimental design. By combining µG experimentation, AI-driven analytics, and biophysical modeling, nVasive aims to become the first clinical diagnostic tool for metastasis prediction, applicable as both a lab diagnostic test (LDT) for precision oncology and a pharmaceutical platform for metastasis-focused drug discovery.

Our objectives in this proposal are strongly aligned with the goals of the CASIS/NASA’s research announcement: 1) We use microgravity and ISS hardware to stimulate utilization of the ISS and economic development in the U.S in the field of precision oncology. 2) Through this proposal, we will improve the existing automation and cell imaging capabilities on-orbit, including in-situ analytical tools, with a higher quality single-cell imaging capability and high-precision automated culture system hardware and software. This will increase the effectiveness of the technology demonstrations and science investigations performed on the ISS. 3) This proposed project will increase the commercial participation in research, technology development, on board services, and other commercial activities. 4) This proposal will broaden the uses of the ISS and its resources by the U.S. commercial sector. 5) nVasive significantly improves patient outcomes, enhances quality of life, and prolongs survival rates. 6) The fundamental knowledge through this proposal will be published in peer-reviewed journals, and contributes to the broader scientific understanding of cancer biology and therapeutic responses, fostering advancements in the field of oncology and paving the way for future innovations. 7) Encapsulate is committed to train the next generation workforce, through extensive engagement with students and educators. Furthermore, the goals of this proposal are in alignment with NASA’s strategic goals: 1. To serve national interests by developing in-space production applications for Earth that strengthen U.S. technological leadership and create high-quality jobs; 2. To provide benefits to humanity by developing products that significantly improve the quality of life for people on earth; and, 3. To enable the development of a robust economy by stimulating scalable and sustainable non-NASA utilization of future commercial destinations or orbital platforms. The development and implementation of nVasive predictive tool for cancer therapy planning hold profound implications for humanity, particularly for cancer patients and their families. By providing personalized treatment strategies tailored to individual patients, Encapsulate significantly improves patient outcomes, enhance quality of life, and prolong survival rates. This advancement in precision oncology not only benefits US citizens but also contributes to global efforts in combating cancer, addressing a critical healthcare challenge on a worldwide scale. Furthermore, the fundamental knowledge generated through our research will be published in peer-reviewed journals, and contributes to the broader scientific understanding of cancer biology and therapeutic responses, fostering advancements in the field of oncology and paving the way for future innovations. Our commitment to sustainable innovation extends beyond Earth's borders, as we aim to harness the potential of low Earth orbit (LEO) for scalable production and innovation. Through these efforts, we are not only advancing scientific knowledge and technological capabilities but also creating opportunities for economic growth, job creation, and sustainable development both on Earth and in space. nVasive technology, is a unique product that aligns a sustainable utilization of LEO productions. Furthermore, the US has been at the forefront of cancer diagnostics and therapy. In recent years, the NIH has launched the Precision Medicine Initiative, with the goal of understanding and increasing knowledge on cancer genetics and biology to find new, more effective treatments.

This is a mature technology (TRL 7+) — the realistic path in is usually NASA's Technology Transfer Program: licensing an existing NASA patent, or a Space Act Agreement to use NASA facilities/expertise directly. NASA also runs a startup licensing program with no upfront fee for companies formed to commercialize a specific NASA technology.

None of these are guaranteed paths for this specific project — TechPort itself doesn't have an "apply" button. Reaching out to the contact(s) above with a specific question is usually the fastest way to find out what's actually open.